Literature DB >> 25595568

Attitudes toward transvaginal mesh among patients in a urogynecology practice.

Sybil G Dessie1, Michele R Hacker, Miriam J Haviland, Peter L Rosenblatt.   

Abstract

INTRODUCTION AND HYPOTHESIS: There has been increasing media attention regarding transvaginal mesh (TVM). We hypothesized that new urogynecology patients have limited knowledge and negative opinions of TVM.
METHODS: An anonymous survey was distributed to all new patients presenting to the Mt Auburn Hospital urogynecology practice from 1 November 2012 to 31 January 2013. A total of 146 patients completed the questionnaire. The survey was designed to elicit information on participants' knowledge and opinions about TVM and knowledge about recent FDA safety communications. All statistical tests were two-sided, and P values <0.05 were considered statistically significant.
RESULTS: Analyses were restricted to the 77 women who had either heard of TVM or were unsure if they had heard of TVM. A minority (32.5 %) of these women correctly defined TVM, and 33.8 % had a negative impression of TVM. Respondents obtained their information on TVM from the media (48.1 %), the Internet (24.7 %), family or friends (22.1 %), and health care providers (18.2 %). The majority (71.4 %) agreed that they needed more information about TVM before making any decisions about using it to treat their condition. Nearly one quarter of respondents (23.4 %) agreed that they would not want their doctor to use TVM on them for any reason. When asked about recent FDA communications, 27.3 % of patients correctly responded that the FDA had released a safety communication regarding TVM.
CONCLUSIONS: The majority of participants had limited knowledge of TVM; however, only a minority had negative opinions. Given our findings, it is important that providers spend more time during the consent process explaining TVM and its risks and benefits as a treatment option.

Entities:  

Mesh:

Year:  2015        PMID: 25595568      PMCID: PMC4457280          DOI: 10.1007/s00192-014-2607-3

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  16 in total

1.  Time to rethink: an evidence-based response from pelvic surgeons to the FDA Safety Communication: "UPDATE on Serious Complications Associated with Transvaginal Placement of Surgical Mesh for Pelvic Organ Prolapse".

Authors:  Miles Murphy; Adam Holzberg; Heather van Raalte; Neeraj Kohli; Howard B Goldman; Vincent Lucente
Journal:  Int Urogynecol J       Date:  2011-11-16       Impact factor: 2.894

2.  Lifetime risk of undergoing surgery for pelvic organ prolapse.

Authors:  Fiona J Smith; C D'Arcy J Holman; Rachael E Moorin; Nicolas Tsokos
Journal:  Obstet Gynecol       Date:  2010-11       Impact factor: 7.661

3.  Surgical repair of anterior wall vaginal defects.

Authors:  S W Bai; H J Jung; M J Jeon; D J Chung; S K Kim; J W Kim
Journal:  Int J Gynaecol Obstet       Date:  2007-06-18       Impact factor: 3.561

Review 4.  Vaginal mesh update.

Authors:  Alex Gomelsky; Roger R Dmochowski
Journal:  Curr Opin Urol       Date:  2012-07       Impact factor: 2.309

5.  Impact of the 2011 FDA transvaginal mesh safety update on AUGS members' use of synthetic mesh and biologic grafts in pelvic reconstructive surgery.

Authors:  Jeffrey L Clemons; Milena Weinstein; Marsha K Guess; Marianna Alperin; Pamela Moalli; William Thomas Gregory; Emily S Lukacz; Vivian W Sung; Bertha H Chen; Catherine S Bradley
Journal:  Female Pelvic Med Reconstr Surg       Date:  2013 Jul-Aug       Impact factor: 2.091

6.  Words of wisdom. Re: FDA public health notification: serious complications associated with transvaginal placement of surgical mesh in repair of pelvic organ prolapse and stress urinary incontinence.

Authors:  Firouz Daneshgari
Journal:  Eur Urol       Date:  2009-05       Impact factor: 20.096

Review 7.  Synthetic vaginal mesh for pelvic organ prolapse.

Authors:  Cheryl B Iglesia
Journal:  Curr Opin Obstet Gynecol       Date:  2011-10       Impact factor: 1.927

8.  The efficacy of Marlex mesh in the repair of severe, recurrent vaginal prolapse of the anterior midvaginal wall.

Authors:  T M Julian
Journal:  Am J Obstet Gynecol       Date:  1996-12       Impact factor: 8.661

9.  Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence.

Authors:  A L Olsen; V J Smith; J O Bergstrom; J C Colling; A L Clark
Journal:  Obstet Gynecol       Date:  1997-04       Impact factor: 7.661

10.  Low-weight polypropylene mesh for anterior vaginal wall prolapse: a randomized controlled trial.

Authors:  Reijo Hiltunen; Kari Nieminen; Teuvo Takala; Eila Heiskanen; Mauri Merikari; Kirsti Niemi; Pentti K Heinonen
Journal:  Obstet Gynecol       Date:  2007-08       Impact factor: 7.661

View more
  3 in total

1.  Native tissue repair or transvaginal mesh for recurrent vaginal prolapse: what are the long-term outcomes?

Authors:  Lin Li Ow; Yik N Lim; Peter L Dwyer; Debjyoti Karmakar; Christine Murray; Elizabeth Thomas; Anna Rosamilia
Journal:  Int Urogynecol J       Date:  2016-06-20       Impact factor: 2.894

Review 2.  Vaginal Approaches Using Synthetic Mesh to Treat Pelvic Organ Prolapse.

Authors:  Jei Won Moon; Hee Dong Chae
Journal:  Ann Coloproctol       Date:  2016-02-29

3.  Temporal Trends of Urogynecologic Mesh Reports to the U.S. Food and Drug Administration.

Authors:  Jessica C Sassani; Amanda M Artsen; Pamela A Moalli; Megan S Bradley
Journal:  Obstet Gynecol       Date:  2020-05       Impact factor: 7.623

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.